# HDM201 Added to CT in R/R or Newly Diagnosed AML

> **NCT03760445** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Novartis Pharmaceuticals**

## Conditions studied

- Leukemia, Myeloid, Acute

## Interventions

- **DRUG:** HDM201
- **DRUG:** cytarabine
- **DRUG:** anthracycline
- **DRUG:** midostaurin
- **DRUG:** liposomal cytarabine/daunorubicin
- **DRUG:** posaconazole
- **DRUG:** midazolam

## Key facts

- **NCT ID:** NCT03760445
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-11-15
- **Primary completion:** 2021-07-22
- **Final completion:** 2023-06-13
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** It was determined that the study design may not be optimal given the changing AML treatment landscape.
- **Last updated:** 2020-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03760445

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03760445, "HDM201 Added to CT in R/R or Newly Diagnosed AML". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03760445. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*